Shares of Insulet Corporation cratered 10.1% to $149.98 after the insulin-pump maker delivered a paradox: a strong quarter followed by a weaker road ahead. Revenue rose 23.5% year over year to $801.7 million , and adjusted EPS of $1.66 beat Wall Street's $1.45 estimate by 14.3% . None of it mattered. The company slashed its full-year U.S. growth outlook to 17%–19% from 20%–22%, pulling total revenue guidance down to 20%–22% . The market punished the stock because guidance tells investors what's coming; a backward-looking beat tells them only where the company has been.
Type 2 Patients Are Quitting Before the 90-Day Mark. Insulet's automated insulin pump still requires patients to manually announce meals and dose insulin — a design that works for type 1 users but is producing a "dropout cliff" among the type 2 patients Insulet has been aggressively recruiting . Reports indicate some type 2 patients discontinue before 90 days, raising concerns about adoption and retention . Over 40% of U.S. new starts were people with type 2 diabetes , meaning this dropout problem sits at the center of the growth thesis.
Management Is Pricing In No Fix This Year. When asked about the timeline for retention initiatives, CEO Ashley McEvoy said the updated guidance "prudently assumes no improvement" in the second half of 2026 . CFO Flavia Pease said roughly two-thirds of the guidance cut stems from sustained retention and utilization headwinds . That conservative framing could provide a cushion — or signal that the company itself doesn't know how deep the problem runs.
The International Business Is Picking Up the Slack — For Now. Insulet raised its international growth outlook to 30%–32% , driven by 33% constant-currency growth and market leadership for new pump users in Australia . It also launched in Spain, its 20th market . Strong overseas momentum offsets some U.S. softness, but international markets carry different reimbursement and pricing dynamics that limit how much profit they can deliver.
The Real Fix Is Still Years Away. Insulet plans to debut an updated pump in 2027 and launch a fully automated system — one requiring no manual meal input — for type 2 patients in 2028 . Until that device arrives, the company is essentially selling a product designed for one patient population to another. Shares have now plunged roughly 53% over the past year , and with the stock trading around 23 times forward earnings, investors must decide whether the type 2 opportunity is merely delayed — or fundamentally oversold.